CYH001

1. SAD Trial Primary Objective: To evaluate the safety and tolerability of a single dose of CYH001 enteric-coated capsules in healthy participants. Secondary Objective: To evaluate the pharmacokinetic characteristics of a single dose of CYH001 enteric-coated capsules in healthy participants. Exploratory Objectives: 1. To assess whether a single dose of CYH001 enteric-coated capsules carries a potential risk of QT/QTc interval prolongation in healthy participants. 2. To identify metabolites in healthy participants after a single dose of CYH001 enteric-coated capsules (if applicable). 2. MAD Trial Primary Objective: To evaluate the safety and tolerability of multiple doses of CYH001 enteric-coated capsules in healthy participants. Secondary Objective: To evaluate the pharmacokinetic characteristics of multiple doses of CYH001 enteric-coated capsules in healthy participants. 3. FE Trial Primary Objective: To evaluate the effect of a high-fat meal on the pharmacokinetics of CYH001 in healthy participants. Secondary objective: To evaluate the safety of a single dose of CYH001 enteric-coated capsules administered after fasting and a high-fat meal in healthy participants.